Skip to main content
Psychedex
Article

2-FA Facts

Stimulant; Substituted amphetamine; Monoamine releasing agent

Description

2-FA (2-fluoroamphetamine) is a synthetic stimulant of the substituted amphetamine class. It releases dopamine and norepinephrine into the brain, producing focused alertness and motivation.

Subjective effects include wakefulness, sharpened focus, motivation, and physical stimulation. The experience is clean and functional — task-oriented alertness without emotional warmth or body load, closer in character to d-amphetamine than to MDMA-adjacent stimulants.

Dependence liability is moderate; the main physical dangers are cardiovascular — raised blood pressure, rapid heart rate, and arrhythmia risk. The short duration drives compulsive redosing, and rodent data confirm 2-FA produces an internal state comparable to methamphetamine.[1]

Dose and durationby route · individual sensitivity varies

Oral(mg)
Threshold< 5 mgLight15 – 30 mgCommon30 – 50 mgStrong50 – 60 mgHeavy60+ mg

Starts in 15 – 30 minLasts 2 – 4 hoursAfter-effects 2 – 6 hours

Body and dependence

Acute toxicity
Moderate
Chronic toxicity
Moderate
Physical dependence
Moderate
Psychological dependence
Moderate
Withdrawal
Mild
Compulsive redosing
High

Tolerance

Builds
Moderate
Fully resets after
5.5 days
Carries over to
amphetamine; methamphetamine; methylphenidate; cocaine; dopaminergic stimulants

Effectslikely at a common dose

Perception
none likely · 6 possible
Body
Pupil dilation; Stimulation; Appetite suppression; Wakefulness; +21 possible, including Temperature dysregulation, Vasoconstriction, Insomnia
Thinking
none likely · 17 possible, including Compulsive redosing urge, Cognitive dysphoria
Feeling
none likely · 8 possible, including Anxiety, Depression, Anhedonia
Self
none likely · 8 possible, including Craving, Ego inflation
Time
none likely · 2 possible
Awareness
Sustained attention (vicara); +1 possible

Who shouldn't take it

Absolute
Severe cardiovascular disease; Concurrent MAOI use; Concurrent tramadol use
Relative
Seizure disorders; Anxiety disorders; Psychotic spectrum conditions; Hepatic impairment; Hyperthyroidism; Pregnancy

Combinations61 recorded

Lethal (2)
MAOIs; Tramadol
Dangerous (28)
Alpha-2 adrenergic receptor antagonist; Anticholinergics; Caffeine; Ephedrine, Pseudoephedrine; GHB, Baclofen; Local anesthetics; MDMA, Amphetamines; MDMA, MDA; NDRIs (Wellbutrin); NRIs; Opioids; SNRIs; SSRIs; Stimulants; 5-HTP, Tryptophan; Antipsychotics; Buspirone; Dopamine agonists; DXM; GHB, GBL; Ibogaine; Ketamine, DXM, PCP; Lithium; NSAIDs; and 4 more, see full page
Caution (28)
See full page: psychedex.org/substances/2-fa
Not graded (3)
Not listed never means safe.

Seek help immediately if

  • Chest pain; racing, pounding, or irregular heartbeat
  • Very high body temperature; heavy sweating; hot, flushed skin
  • Severe agitation, paranoia, panic, or confusion
  • Severe headache; muscle rigidity or twitching
  • Seizures
  • Signs of stroke — face drooping, one-sided weakness, slurred speech
  • Difficulty breathing; collapse or unconsciousness

What to do

  1. Call emergency services for chest pain, overheating, seizure, or unresponsiveness
  2. Move them to a cool, quiet place and reduce stimulation
  3. Cool the body — remove excess clothing, apply cool damp cloths, fan them
  4. Keep them calm; reassure — panic worsens the cardiovascular strain
  5. If seizing, protect from injury (don't restrain); recovery position afterward
  6. Monitor breathing and be ready to give rescue breaths / CPR

Most stimulant overdoses settle with cooling, a calm environment, and time. The medical danger is hyperthermia, cardiac events (arrhythmia, heart attack, stroke), and seizures — get help immediately if any appear.

988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE

Version r1.a1 · Not medical advice

References

  1. [1]
    ^Anchondo O, Shetty RA, Gatch MB (2025) Locomotor and discriminative stimulus effects of fluorinated analogs of amphetamine and methamphetamine in mice and rats — Journal of Pharmacology and Experimental Therapeutics doi:10.1016/j.jpet.2025.103617
Print version
Report an issue